The Lynx Group

ASCO 2014 – Colorectal and Head & Neck Cancer

This was a retrospective analysis of the phase 3 IMCL-9815 trial assessing the role of HPV-p16 status in patients with locally advanced SCCHN receiving radiation therapy (RT) plus cetuximab (cetux) or RT alone (Rosenthal DI, et al. ASCO 2014. Abstract 6001).
Read Article

Platinum-based chemoradiation therapy (CRT) is the current standard treatment for locally advanced SCCHN, and induction docetaxel/cisplatin/5-fluorouracil (TPF) is superior to cisplatin/5-fluorouracil alone, but it has not been tested when added to concomitant therapy.
Read Article

In the E2399 trial, HPV+ patients with oropharyngeal squamous cell carcinoma (OPSCC) attained 2-year overall survival (OS) of 95% and progression-free survival (PFS) of 86% when treated with induction chemotherapy (IC) and 70 Gy chemoradiation.
Read Article

In many cancers, KRAS mutations can predict cancer risk, unique cancer biology, and response to certain therapeutic agents. RTOG 0522 was a phase 3 trial of cisplatin/radiation ± cetuximab for patients with locally advanced SCCHN, evaluating whether KRAS mutation status would predict the response to cetuximab in these patients (Weidhaas JB, et al. ASCO 2014. Abstract 6000).
Read Article







Page 1 of 3


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: